Aptamer F5R1 against a-Synuclein in Parkinson’s Disease Aptamer Details
ID# 9527
Structure
Chemistry
DNA
Target
a-Synuclein in Parkinson's Disease
Category
Protein
Affinity (Kd)
2.40 nM
Length
60
Aptazyme
No
Sequence (3-char table code)
G
A
C
U/T
5'-dApdTpdCpdGpdApdGpdTpdGpdTpdGpdTpdApdCpdGpdGpdGpdGpdTpdCpdCpdGpdGpdTpdApdGpdGpdGpdTpdGpdGpdCpdGpdApdGpdGpdTpdCpdTpdTpdCpdCpdTpdGpdTpdCpdGpdTpdApdGpdCpdApdGpdGpdApdTpdCpdCpdAp-3'
Molecular Weight: 18057.7 g/mole
Extinction Coefficient: 560900
Binding Conditions / Buffer
PBS, 1 mM MgCI2, pH 7.4
Binding Temp: 25°C
Refolding Protocol
Note: Information on this aptamer oligo was obtained from the literature and hasn't been validated by Aptagen.
Reference
Zheng, Y., Qu, J., Xue, F., Zheng, Y., Yang, B., Chang, Y., Yang, H., & Zhang, J. (2018). Novel DNA Aptamers for Parkinson's Disease Treatment Inhibit α-Synuclein Aggregation and Facilitate its Degradation. Molecular therapy. Nucleic acids, 11, 228–242. https://doi.org/10.1016/j.omtn.2018.02.011
Request a Quote
Have your aptamer oligo synthesized by Aptagen.
